Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CompARE: Escalating Treatment in Intermediate and High-risk Oropharyngeal Cancer
NCT04116047Phase 3Active, not recruiting
- Sponsor
- University of Birmingham
- Start
- Jul 2015
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of durvalumab in oropharyngeal cancer (2 arms), sponsored by University of Birmingham. Primary endpoints: Overall Survival at 8 years and Event Free Survival at 8 years. Started Jul 2015; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
oropharyngeal cancer
Beyond the preview
Go deeper on NCT04116047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04116047.